Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 14Ovarian Neoplasms 12Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lymphoma 3Lung Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Hereditary Breast and Ovarian Cancer Syndrome 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Zollinger-Ellison Syndrome 1Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × veliparib × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT01085422 2017-11-21

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

AbbVie

Phase 1 Completed
35 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡